Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - July 2013


Pharmacokinetics in Drug Development - for the Non-Specialist

01 Jul 2013 - 02 Jul 2013 - London, UK



Bookmark and Share


In drug development clinical pharmacology is tasked to ensure that patients receive the right dose at the right time. This ensures that the new medicine is safe and effective throughout the patient population. To achieve this goal, it is necessary to recognise the factors that can alter drug response. Knowledge of pharmacokinetics (PK) and pharmacokinetic/pharmacodynamic (PK/PD) relationships is at the heart of this endeavour. For many drugs, clinical pharmacology information accounts for almost 50% of the final drug label, further emphasising the importance of PK understanding in drug development.

Course Objectives

To provide participants with an overview of the principles of Pharmacokinetics and Pharmacokinetic/Pharmacodynamic modelling and how, together with regulatory guidances, they can be used to effectively deliver drug development programmes

What will participants gain-

  • Increased confidence to discuss PK issues within their drug projects
  • Understanding of the common PK terms and their importance
  • Understanding of how PK data influences the clinical development programme
  • An understanding of the factors that contribute to variability in PK
  • The role of PK/PD modelling in drug development
  • An appreciation of how regulatory guidances influence PK

Who Should Attend?

The course is intended for all professionals in the drug development arena especially those that work in or with clinical project teams (eg Regulatory Affairs specialists; Medical personnel; Project managers/leaders; Clinical research associates, Medical writers) who want to further their knowledge of the usefulness of PK in their projects.

Numbers are restricted for maximum benefit to participants

Course Programme

Course will commence with registration at 8.30am, course proper at 9.00am and will finish at 5.00pm each day.

Day 1: Pharmacokinetic Principles

The principle processes involved in PK will be discussed and the jargon used in their description and quantification will be explained.

What is PK and why is it important

  • Absorption, distribution, metabolism and elimination
  • Therapeutic windows
  • PK terminology
  • Clearance, Volume of distribution

PK techniques

  • Non compartmental Analysis
  • Compartmental modelling
  • PK/PD modelling
  • Regulatory environment
  • Data interpretation
  • Reporting

Day 2: PK in Drug Development

The application of PK in clinical development will be addressed by looking at questions that commonly arise within drug projects. Examples include: "What are the implications of pre-clinical PK findings on the design of early phase development studies"; "How is the clinical relevance of a drug drug interaction assessed" and "What are the sources of variability in pharmacokinetic response".

Early phase development

  • Dose choice in first in human studies
  • Drug interactions; CYPs and transporters, strategies and regulatory guidance; types of interaction competitive vs mechanism based; co-medication strategy for patient studies
  • Radiolabel studies to assess routes of elimination
  • Assessing bioequivalence (oral and inhaled routes)

Variability in PK

  • Genetic polymorphisms
  • Influence of age
  • Food effects

Several "learning in action" workshops during both days will provide participants with the opportunity to apply knowledge gained during the lectures.

Participants will need to bring along a scientific calculator



Further information
Scientific News
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
A Better Model for Parkinson's
Scientists at EPFL solve a longstanding problem with modeling Parkinson’s disease in animals. Using newfound insights, they improve both cell and animal models for the disease, which can propel research and drug development.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
Microalgae Make a Splash in the UK Cosmeceutical Market
Scottish innovators have discovered an anti-viral and anti-inflammatory carbohydrate in microscopic algae (microalgae) which has huge potential to change the cosmetics market.
Mechanism of Tumor Suppressing Gene Uncovered
The most commonly mutated gene in cancer,p53, works to prevent tumor formation by keeping mobile elements in check that otherwise lead to genomic instability, UT Southwestern Medical Center researchers have found.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
Useful Colon Cancer Biomarker Discovered
Biomarker is detectable with simple, inexpensive test.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Seeing Hope
Gene therapy/drug combo restores some vision in mice with optic nerve injury.
Versatile New Molecule-Building Technique
Chemists at The Scripps Research Institute (TSRI) have devised a new and widely applicable technique for building potential drug molecules and other organic compounds.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!